TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
![Thumbnail](/bitstream/handle/internal/5578/PIIS2405630822001094.pdf.jpg?sequence=5&isAllowed=y)
View/ Open
Date
2022-11-01Author
Thomson, DJ
Cruickshank, C
Baines, H
Banner, R
Beasley, M
Betts, G
Bulbeck, H
Charlwood, F
Christian, J
Clarke, M
Donnelly, O
Foran, B
Gillies, C
Griffin, C
Homer, JJ
Langendijk, JA
Lee, LW
Lester, J
Lowe, M
McPartlin, A
Miles, E
Nutting, C
Palaniappan, N
Prestwich, R
Price, JM
Roberts, C
Roe, J
Shanmugasundaram, R
Simões, R
Thompson, A
West, C
Wilson, L
Wolstenholme, J
Hall, E
Type
Journal Article
Metadata
Show full item recordAbstract
•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.
Collections
Research team
Clin Trials & Stats Unit
Language
eng
Date accepted
2022-11-18
License start date
2022-11-01
Citation
Clinical and Translational Radiation Oncology, 2022,
Publisher
ELSEVIER IRELAND LTD